<unk>  is used to treat different kinds of bacterial infections, including complicated skin and structure infections, complicated intra-abdominal infections and community-acquired bacterial pneumonia.<unk>  is a glycylcycline antibiotic that covers MRSA and Gram-negative organisms: *<unk>  can treat complicated skin and structure infections caused by; Escherichia coli, vancomycin-susceptible Enterococcus faecalis, methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus agalactiae, Streptococcus anginosus grp., Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis. *<unk>  is indicated for treatment of complicated intra-abdominal infections caused by; Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, vancomycin-susceptible Enterococcus faecalis, methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus anginosus grp., Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus micros. *<unk>  may be used for treatment of community-acquired bacterial pneumonia caused by; penicillin susceptible Streptococcus pneumoniae, Haemophilus influenzae that does not produce Beta-lactamase and Legionella pneumophila.<unk>  is given intravenously and has activity against a variety of Gram-positive and Gram-negative bacterial pathogens, many of which are resistant to existing antibiotics.<unk>  successfully completed phase III trials in which it was at least equal to intravenous vancomycin and aztreonam to treat complicated skin and skin structure infections, and to intravenous imipenem and cilastatian to treat complicated intra-abdominal infections.<unk>  is active against many Gram-positive bacteria, Gram-negative bacteria and anaerobes – including activity against methicillin-resistant Staphylococcus aureus (MRSA), Stenotrophomonas maltophilia, Haemophilus influenzae, and Neisseria gonorrhoeae (with MIC values reported at 2 µg/mL) and multi-drug resistant strains of Acinetobacter baumannii. It has no activity against Pseudomonas spp. or Proteus spp. The drug is licensed for the treatment of skin and soft tissue infections as well as intra-abdominal infections. The European Society of Clinical Microbiology and Infection recommends<unk>  as a potential salvage therapy for severe and/or complicated or refractory Clostridium difficile infection.<unk>  can also be used in vulnerable populations such as immunocompromised patients or patients with cancer.<unk>  may also have potential for use in acute myeloid leukemia. Susceptibility data<unk>  targets both Gram-positive and Gram-negative bacteria including a few key multi-drug resistant pathogens. The following represents MIC susceptibility data for a few medically significant bacterial pathogens. * Escherichia coli: 0.015 μg/mL — 4 μg/mL * Klebsiella pneumoniae: 0.06 μg/mL — 16 μg/mL * Staphylococcus aureus (methicillin-resistant): 0.03 μg/mL — 2 μg/mL<unk>  generally has poor activity against most strains of Pseudomonas. Liver or kidney problems<unk>  does not require dose adjustment for people with mild to moderate liver problems. However, in people with severe liver problems dosing should be decreased and closely monitored.<unk>  does not require dose changes in people with poor kidney function or having hemodialysis. Resistance mechanisms Bacterial resistance towards<unk>  in Enterobacteriaceae (such as E. coli) is often caused by genetic mutations leading to an up-regulation of bacterial efflux pumps, such as the RND type efflux pump AcrAB. Some bacterial species such as Pseudomonas spp. can be naturally resistant to<unk>  through the constant over-expression of such efflux pumps. In some Enterobacteriaceae species, mutations in ribosomal genes such as rpsJ have been found to cause resistance to<unk> .
Tigecycline
Daptomycin
Linezolid
Telithromycin
Delafloxacin
Teicoplanin
Merafloxacin
Doxycycline